{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:35:27Z","timestamp":1776890127744,"version":"3.51.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2023 Jinan Science and Technology Program","award":["202328003"],"award-info":[{"award-number":["202328003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>To explore and analyze the potential adverse event (AE) signals of trazodone, with reference to the safe clinical use of drugs. Based on the FDA Adverse Event Reporting System (FAERS), the AE data of trazodone were extracted from the first quarter of 2004 to the second quarter of 2024, and the extracted data were statistically analyzed using the method, to identify valid AE signals that met our judgment, compare them with those recorded in the authorized information for trazodone thereby identifying unexpected potential adverse reactions. A total of 5199 AE reports with trazodone as the main suspect were extracted, with a higher reported proportion of females (52.68%) than males (38.83%). Many reports (31.47%) did not provide age information, although for those reports with identifiable age data, the 50\u201360 years age group was the most common (14.20%), and the country of reporting was predominantly the United States (82.58%). A total of 179 significant AE signals were unearthed, with suicide, formulation toxicity, abnormal penile erection, insomnia, and cardiac and respiratory arrest reported with high frequency, which was not entirely consistent with the specification record. The study unearthed 156 new potential AEs on the basis of trazodone drug inserts and suggested precautions for overdosing and dose adjustment, which is conducive to safeguarding the safety of patients\u2019 medication.<\/jats:p>","DOI":"10.1038\/s41598-025-89632-7","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T04:02:48Z","timestamp":1739419368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"given":"Yong","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yankui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"89632_CR1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/00002826-198901001-00002","volume":"12","author":"B Silvestrini","year":"1989","unstructured":"Silvestrini, B. Trazodone: from the mental pain to the dys-stress hypothesis of depression. Clin. Neuropharmacol. 12, S4\u201310 (1989).","journal-title":"Clin. Neuropharmacol."},{"issue":"10","key":"89632_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1017\/S1092852900024020","volume":"14","author":"SM Stahl","year":"2009","unstructured":"Stahl, S. M. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 14 (10), 536\u2013546 (2009).","journal-title":"CNS Spectr."},{"issue":"1","key":"89632_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson, E. & Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68 (1), 29\u201339 (2000).","journal-title":"Life Sci."},{"issue":"2","key":"89632_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s00210-004-0951-4","volume":"370","author":"AR Knight","year":"2004","unstructured":"Knight, A. R. et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2\u00a0C) receptors. Naunyn Schmiedebergs Arch. Pharmacol. 370 (2), 114\u2013123 (2004).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"89632_CR5","doi-asserted-by":"crossref","unstructured":"Coin, A. et al. Real-world use of trazodone in older persons in long term care setting: a retrospective study. Int. J. Geriatr. Psychiatry 39(11), e70009 (2024).","DOI":"10.1002\/gps.70009"},{"key":"89632_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/YIC.0000000000000304","volume":"35","author":"A Fagiolini","year":"2020","unstructured":"Fagiolini, A. et al. Arandomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Int. Clin. Psychopharmacol. 35, 137\u2013146 (2020).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"89632_CR7","first-page":"137","volume":"54","author":"A Cuomo","year":"2019","unstructured":"Cuomo, A. et al. Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice. Riv Psichiatr. 54, 137\u2013149 (2019).","journal-title":"Riv Psichiatr"},{"issue":"4","key":"89632_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5414\/CP204068","volume":"60","author":"KD Sharma","year":"2022","unstructured":"Sharma, K. D., Colangelo, T. & Mills, A. Trazodone-induced parkinsonism: a case report. Int. J. Clin. Pharmacol. Ther. 60 (4), 184\u2013187 (2022).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"3","key":"89632_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JCP.0000000000001832","volume":"44","author":"P Haghparast","year":"2024","unstructured":"Haghparast, P., Nadybal, M. & Yuan, C. Treatment-resistant priapism in a 61-year-old male after combined use of trazodone, quetiapine, and fluoxetine. J. Clin. Psychopharmacol. 44 (3), 316\u2013317 (2024).","journal-title":"J. Clin. Psychopharmacol."},{"key":"89632_CR10","doi-asserted-by":"publisher","first-page":"1369384","DOI":"10.3389\/fphar.2024.1369384","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen, S., Fang, W., Zhao, L. & Xu, H. Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database. Front. Pharmacol. 15, 1369384 (2024).","journal-title":"Front. Pharmacol."},{"key":"89632_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","volume":"354","author":"R Lu","year":"2024","unstructured":"Lu, R. et al. Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database. J. Affect. Disord. 354, 649\u2013655 (2024).","journal-title":"J. Affect. Disord"},{"issue":"8","key":"89632_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M., Raschi, E., Poluzzi, E. & Hauben, M. The evolving role of disproportionality analysis in pharmacovigilance. Expert Opin. Drug Saf. 23 (8), 981\u2013994 (2024).","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"89632_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pds.1058","volume":"14","author":"N Moore","year":"2005","unstructured":"Moore, N., Thiessard, F. & Begaud, B. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf. 14 (4), 285\u2013286 (2005).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"89632_CR14","doi-asserted-by":"publisher","first-page":"1349636","DOI":"10.3389\/fimmu.2024.1349636","volume":"15","author":"L Ding","year":"2024","unstructured":"Ding, L., Chen, C., Yang, Y. & Zhang, X. Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data. Front. Immunol. 15, 1349636 (2024).","journal-title":"Front. Immunol."},{"issue":"7","key":"89632_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10 (7), 796\u2013803 (2013).","journal-title":"Int. J. Med. Sci."},{"issue":"9","key":"89632_CR16","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00228-020-02909-w","volume":"76","author":"K Tada","year":"2020","unstructured":"Tada, K., Maruo, K., Isogawa, N., Yamaguchi, Y. & Gosho, M. Borrowing external information to improve bayesian confidence propagation neural network. Eur. J. Clin. Pharmacol. 76 (9), 1311\u20131319 (2020).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"89632_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S2215-0366(16)30263-2","volume":"4","author":"C Kuehner","year":"2017","unstructured":"Kuehner, C. Why is depression more common among women than among men? Lancet Psychiatry. 4 (2), 146\u2013158 (2017).","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"89632_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14737175.2024.2363843","volume":"24","author":"I Berardelli","year":"2024","unstructured":"Berardelli, I. et al. Rethinking the role of trazodone in the different depressive dimensions. Expert Rev. Neurother. 24 (7), 619\u2013632 (2024).","journal-title":"Expert Rev. Neurother."},{"issue":"1\u20133","key":"89632_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jad.2013.01.004","volume":"147","author":"K Hawton","year":"2013","unstructured":"Hawton, K., Casa\u00f1as, I., Comabella, C., Haw, C. & Saunders, K. Risk factors for suicide in individuals with depression: a systematic review. J. Affect. Disord. 147 (1\u20133), 17\u201328 (2013).","journal-title":"J. Affect. Disord"},{"issue":"10","key":"89632_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1017\/S0033291718002301","volume":"49","author":"M Dong","year":"2019","unstructured":"Dong, M. et al. Prevalence of suicide attempt in individuals with major depressive disorder: a meta-analysis of observational surveys. Psychol. Med. 49 (10), 1691\u20131704 (2019).","journal-title":"Psychol. Med."},{"issue":"12","key":"89632_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","volume":"26","author":"A Fagiolini","year":"2012","unstructured":"Fagiolini, A. et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 26 (12), 1033\u20131049 (2012).","journal-title":"CNS Drugs"},{"issue":"4","key":"89632_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.euroneuro.2017.10.032","volume":"28","author":"F Artigas","year":"2018","unstructured":"Artigas, F., Bortolozzi, A. & Celada, P. Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies. Eur. Neuropsychopharmacol. 28 (4), 445\u2013456 (2018).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"89632_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/jama.292.3.338","volume":"292","author":"H Jick","year":"2004","unstructured":"Jick, H., Kaye, J. A. & Jick, S. S. Antidepressants and the risk of suicidal behaviors. JAMA 292, 338\u2013343 (2004).","journal-title":"JAMA"},{"key":"89632_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1176\/appi.ajp.163.1.41","volume":"163","author":"GE Simon","year":"2006","unstructured":"Simon, G. E., Savarino, J., Operskalski, B. & Wang, P. S. Suicide risk during antidepressant treatment. Am. J. Psychiatry. 163, 41\u201347 (2006).","journal-title":"Am. J. Psychiatry"},{"key":"89632_CR25","first-page":"294","volume":"52","author":"CM Beasley","year":"1991","unstructured":"Beasley, C. M., Dornseif, B. E., Pultz, J. A., Bosomworth, J. C. & Sayler, M. E. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J. Clin. Psychiatry. 52, 294\u2013299 (1991).","journal-title":"J. Clin. Psychiatry"},{"key":"89632_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/00004714-199406000-00004","volume":"14","author":"RH Weisler","year":"1994","unstructured":"Weisler, R. H. et al. Comparison of bupropion and trazodone for the treatment of major depression. J. Clin. Psychopharmacol. 14, 170\u2013179 (1994).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"89632_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2013.11.008","volume":"65","author":"A Salonia","year":"2014","unstructured":"Salonia, A. et al. European association of urology guidelines on priapism. Eur. Urol. 65 (2), 480\u2013489 (2014).","journal-title":"Eur. Urol."},{"issue":"3","key":"89632_CR28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.sxmr.2020.10.003","volume":"9","author":"T Hwang","year":"2021","unstructured":"Hwang, T., Shah, T. & Sadeghi-Nejad, H. A review of antipsychotics and priapism. Sex. Med. Rev. 9 (3), 464\u2013471 (2021).","journal-title":"Sex. Med. Rev."},{"issue":"1","key":"89632_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/JCP.0b013e3181c8273d","volume":"30","author":"F Andersohn","year":"2010","unstructured":"Andersohn, F., Schmedt, N., Weinmann, S., Willich, S. N. & Garbe, E. Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J. Clin. Psychopharmacol. 30 (1), 68\u201371 (2010).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"89632_CR30","first-page":"09l00816","volume":"12","author":"P Hoffmann","year":"2010","unstructured":"Hoffmann, P., Neu, E. T. & Neu, D. Penile amputation after trazodone-induced priapism: a case report. Prim. Care Companion J. Clin. Psychiatry. 12 (2), 09l00816 (2010).","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"issue":"6","key":"89632_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/15622975.2018.1520396","volume":"20","author":"T Greiner","year":"2019","unstructured":"Greiner, T. et al. Priapism induced by various psychotropics: a case series. World J. Biol. Psychiatry. 20 (6), 505\u2013512 (2019).","journal-title":"World J. Biol. Psychiatry"},{"issue":"4","key":"89632_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1176\/appi.psy.46.4.367","volume":"46","author":"G Jayaram","year":"2005","unstructured":"Jayaram, G. & Rao, P. Safety of trazodone as a sleep agent for inpatients. Psychosomatics 46 (4), 367\u2013369 (2005).","journal-title":"Psychosomatics"},{"issue":"6","key":"89632_CR33","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1592\/phco.23.6.754.32185","volume":"23","author":"W Alvarez Jr","year":"2003","unstructured":"Alvarez, W. Jr. & Pickworth, K. K. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 23 (6), 754\u2013771 (2003).","journal-title":"Pharmacotherapy"},{"key":"89632_CR34","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.12659\/AJCR.919833","volume":"20","author":"KK Soe","year":"2019","unstructured":"Soe, K. K. & Lee, M. Y. Arrhythmias in severe trazodone overdose. Am. J. Case Rep. 20, 1949\u20131955 (2019).","journal-title":"Am. J. Case Rep."},{"key":"89632_CR35","doi-asserted-by":"crossref","unstructured":"Mohan, G., Ajitkumar, A., Bhide, P., Ravilla, J. & Kramer, V. Trazodone overdose manifesting as hypotension and qt prolongation. Cureus 15(3), e36871 (2023).","DOI":"10.7759\/cureus.36871"},{"issue":"12","key":"89632_CR36","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1080\/15563650.2020.1746330","volume":"58","author":"SL Campleman","year":"2020","unstructured":"Campleman, S. L. et al. Drug-specific risk of severe QT prolongation following acute drug overdose. Clin. Toxicol. (Phila). 58 (12), 1326\u20131334 (2020).","journal-title":"Clin. Toxicol. (Phila)"},{"issue":"2","key":"89632_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00210-004-0952-3","volume":"370","author":"E Zitron","year":"2004","unstructured":"Zitron, E. et al. Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn Schmiedebergs Arch. Pharmacol. 370 (2), 146\u2013156 (2004).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"3","key":"89632_CR38","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.4103\/jfmpc.jfmpc_645_23","volume":"13","author":"AL Schneider","year":"2024","unstructured":"Schneider, A. L. Trazodone-related oromandibular dyskinesia. J. Family Med. Prim. Care. 13 (3), 1103\u20131105 (2024).","journal-title":"J. Family Med. Prim. Care"},{"issue":"1","key":"89632_CR39","first-page":"70","volume":"33","author":"B Yilba\u015f","year":"2022","unstructured":"Yilba\u015f, B. Restless legs syndrome due to the use of trazodone: a case report. Turk. Psikiyatri Derg. 33 (1), 70\u201372 (2022).","journal-title":"Turk. Psikiyatri Derg"},{"issue":"10","key":"89632_CR40","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/toxins14100680","volume":"14","author":"NP Skarmeta","year":"2022","unstructured":"Skarmeta, N. P., Katzmann, G. C., Vald\u00e9s, C., Gaedechens, D. & Montini, F. C. Tardive oromandibular dystonia induced by trazodone: a clinical case and management from the perspective of the dental specialist. Toxins (Basel). 14 (10), 680 (2022).","journal-title":"Toxins (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89632-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T04:02:56Z","timestamp":1739419376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89632-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89632"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89632-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"was not required for this study, because all data were publicly available and ethical approval and informed consent were obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"5322"}}